# Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
Canonical URL: https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-provides-first-quarter-2026-corporate-update
Ticker: BJDX
Company: Bluejay Diagnostics
Source: Bluejay Diagnostics
Published: 2026-05-07 20:01 EST
Original Source URL: https://ir.bluejaydx.com
## Summary

ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and

## Article Body
ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and
## Recent Company News
- 2026-06-02 16:19 EST — [Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-up-to-23-6-million-private-placement-priced-at-the-market-under-nasdaq-rules) — Source: Bluejay Diagnostics
- 2026-06-02 10:30 EST — [Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-and-argonaut-manufacturing-services-announce-strategic-partnership) — Source: Bluejay Diagnostics
- 2026-05-07 20:01 EST — [Bluejay Diagnostics Provides First Quarter 2026 Corporate Update](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-provides-first-quarter-2026-corporate-update) — Source: Bluejay Diagnostics
- 2026-04-07 10:30 EST — [Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial) — Source: Bluejay Diagnostics
- 2026-03-12 10:30 EST — [Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting](https://biopharmsignal.com/news/BJDX/bluejay-announces-abstract-accepted-for-presentation-at-the-2026-society-of-academic-emergency-medicine-saem-annual-meeting) — Source: Bluejay Diagnostics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)